
Opinions
Mark Grammer
Teva PharmaceuticalTEVADON'T BUYNov 20, 2017
$13.08
Stock price when the opinion was issued
$31.48
As of Jun 18, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
He has not been in it for a long time. It is a very competitive space and a few drugs were up against competition. He has not got excited about it and has not invested in it.